CVrg will be on the ground in New Orleans covering key sessions at ACC 2026.
Conference Coverage details: cv-rg.com/conferences/
#ACC26 #Cardiology #HeartFailure #ClinicalTrials #HFPEF #oHCM #pulmonaryhypertension #CVrg
1/22 In this #CME, Dr. Milind Desai provides guidance on #oHCM, including making the diagnosis, staying up-to-date on cardiac myosin inhibitors, and addressing patients’ concerns.
Get credit: link.med-iq.com/oXPP2o
1/22 In this #CME #MedX, @DesaiMilindY provides guidance on #oHCM, including making the diagnosis, staying up-to-date on cardiac myosin inhibitors, and addressing patients’ concerns.
Get credit: link.med-iq.com/oXPP2o
The third slide from the August 2025 issue of Journal Watch, titled "Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 128 Results From VALOR-HCM." For a more screenreader friendly version, the full issue PDF is at https://www.ishlt.org/docs/default-source/journal-watch/2025-08-journalwatch-cardiology.pdf.
In last month's #ISHLTJournalWatch, #BhanuRamachandran reviews a study led by Milind Y. Desai on the use of #Mavacamten in patients with obstructive hypertrophic #cardiomyopathy ( #oHCM ). Can Mavacamten allow clinicians to defer or avoid SRT use in these patients?
#ISHLT #CardioSky #TransplantSky
EMORI-HCM: Electromechanically optimized right ventricular pacing improves symptoms, exercise capacity and #LVOT gradient in patients with #oHCM.
Learn more about this late-breaking clinical trial in #JACC: https://bit.ly/4mznIRP
#ESCCongress #WCCardio #CardioSky #MedSky
From Ahmad Masri, MD et al in JACC Heart Failure: 1-yr FOREST-HCM OLE update
Ongoing efficacy of aficamten for #oHCM
• No HF events
• No new AF
• Low rate asx ⬇️LVEF (managed w/ dose reduction)
More at #ESC2025! @jaccjournals.bsky.social #CardioSky #MedSky
🔗 Full update: link.med-iq.com/MEKZHn
#JACCBTS study identified 3 subtypes of #oHCM in pts who underwent septal reduction therapy:
1️⃣ Sarcomere mutation–rich, thick IVS
2️⃣ LA enlargement, high #AFib burden
3️⃣ ⬆️#LVOT gradient, inflammation, ⬆️ postop events
Validated in 2 cohorts jacc.org/doi/10.1016/...
LBCT insights from SEQUOIA-HCM at #HeartFailure2025: #aficamten as effective in mildly symptomatic pts w/ #oHCM (NYHA class II/KCCQ-CSS ≥80) as in pts w/ moderate to severe sx. Now published in EHJ! doi.org/10.1093/eurheartj/ehaf364 #CardioSky #MedSky
Data from the Explorer, Valor and Sequoia trials led to the recommended treatment guidelines for the management of #oHCM. #CardioSky #MedSky #HCM #Cardiology @accintouch.bsky.social @americanheart.bsky.social
The MAPLE-HCM study evaluates #aficamten vs #metoprolol to potentially redefine first-line therapy standards in hypertrophic obstructive cardiomyopathy. Details of the study design in #JACCHF: www.jacc.org/doi/10.1016/...
#oHCM #HCMAwarenessDay
Yes I agree, it helped that my cardiologist recognized I have a genetic heart problem #oHCM so I feel very blessed for that and I am getting the care I need. It's still new, BUT I do feel better because of my Healthier living. Thanks to #cdnhealth So glad to be #Canadian and living in BC #bcpoli
📌 Impact of #Aficamten on Disease & Symptom Burden in Obstructive Hypertrophic Cardiomyopathy: Results From #SEQUOIAHCM
https://buff.ly/3Oz3PuN
#OHCM #HCM
